Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
作者机构：Kolling Institute of Medical ResearchUniversity of SydneyRoyal North Shore HospitalSydneyNSW 2065Australia. School of Life and Environmental SciencesUniversity of SydneySydney NSW 2008Australia. College of Medicine and Public HealthFlinders UniversityBedford ParkAdelaideSA 5042Australia.
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2020年第3卷第3期
页 面：532-549页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Beat Cancer Cancer Council South Australia
主 题：Chronic lymphocytic leukaemia drug resistance targeted cancer therapy
摘 要：The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years,first by the introduction of chemoimmunotherapy regimens and subsequently by the development of drugs,including ibrutinib,idelalisib and venetoclax,that target components of the B-cell receptor signalling pathway or B-cell lymphoma 2 family of *** high initial response rates in patients treated with chemoimmunotherapy or targeted agents,a significant proportion of patients relapse with progressive and refractory *** a subset of these patients,drug resistance has been associated with specific genetic lesions or activation of alternate pro-survival ***,the mechanisms that confer drug resistance in the remainder of the patients with refractory disease have yet to be fully *** this review,we discuss our current understanding of the mechanics of drug resistance in chronic lymphocytic leukaemia and describe how this knowledge may aid in rationalising future treatment strategies to prevent the development of refractory or aggressive transformation of the disease.
维普期刊数据库